NYSE:GMED - Globus Medical Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $42.60 -0.56 (-1.30 %) (As of 05/19/2019 04:00 PM ET)Previous Close$42.60Today's Range$42.52 - $43.7652-Week Range$38.01 - $57.83Volume352,298 shsAverage Volume654,669 shsMarket Capitalization$4.22 billionP/E Ratio25.51Dividend YieldN/ABeta0.79 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Globus Medical (NYSE:GMED) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.9 Wall Street analysts have issued ratings and price targets for Globus Medical in the last 12 months. Their average twelve-month price target is $56.8889, suggesting that the stock has a possible upside of 33.54%. The high price target for GMED is $65.00 and the low price target for GMED is $49.00. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyBuyHoldHoldConsensus Rating Score: 2.562.562.452.45Ratings Breakdown: 1 Sell Rating(s)2 Hold Rating(s)6 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)2 Hold Rating(s)6 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)4 Hold Rating(s)6 Buy Rating(s)0 Strong Buy Rating(s)2 Sell Rating(s)2 Hold Rating(s)7 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $56.8889$58.3333$55.9091$55.8182Price Target Upside: 33.54% upside22.06% upside28.56% upside8.98% upsideGlobus Medical (NYSE:GMED) Consensus Price Target History Globus Medical (NYSE:GMED) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails5/3/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$57.00 ➝ $52.00High3/19/2019OppenheimerReiterated RatingHoldLow3/1/2019Cantor FitzgeraldReiterated RatingBuy$60.00Low2/28/2019UBS GroupUpgradeNeutral ➝ Buy$55.00High1/2/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$64.00 ➝ $49.00High12/17/2018Credit Suisse GroupInitiated CoverageOutperform$53.00Medium11/9/2018Leerink SwannBoost Price TargetOutperform$61.00 ➝ $65.00Low11/9/2018Piper Jaffray CompaniesBoost Price TargetOverweight$62.00Low6/27/2018Bank of AmericaDowngradeNeutral ➝ Underperform$55.00High4/16/2018BTIG ResearchReiterated RatingBuy ➝ Neutral$37.00Low3/12/2018Canaccord GenuityReiterated RatingBuy$53.00Low1/10/2018BarclaysReiterated RatingSell$36.00Medium1/10/2018Wells Fargo & CoReiterated RatingOutperform$46.00 ➝ $51.00High11/14/2017GabelliReiterated RatingBuyN/A(Data available from 5/19/2017 forward) This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Mutual Funds Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.